Spexis AG

Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 07.06.2024/nPublicly viewable until: 07.06.2025/nPublication number: UP04-0000006399/nPublishing entity/nVISCHER AG - MST, Aeschenvorstadt 4.

4010 Basel/nInvitation to the ordinary general meeting Spexis/nAG/nOrganisation concerned:
/nSpexis AG/nCHE-108.535.251/nHegenheimermattweg 125/n4123 Allschwil/nGeneral meeting details:/n28.06.2024, 15.00 Uhr.

Spexis AG/nHegenheimermattweg 125/n4123 Allschwil/nInvitation/Agenda:
/nsee attachment/nAGENDA OF THE MEETING/n1. Approval of the unaudited Management Report and the Consolidated Accounts (IFRS) for the/n year 2023 and the unaudited Annual Accounts (statutory) of Spexis AG for the year 2023/n The Board of Directors proposes approval of the unaudited management report and the consolidated/n accounts (IFRS) for the year 2023 and the unaudited annual accounts (statutory) of Spexis AG for the/n year 2023./n2. Allocation of the Balance Sheet Result/n The Board of Directors proposes to carry forward the net loss of the year 2023 amounting to/n CHF 39'398'557 under Swiss statutory accounts./n3. Increase of the Capital Band (replaces Authorized Share Capital)/n The Board of Directors proposes to increase the number of shares issuable under the capital band/n and to replace article 3a paragraphs 1 and 2 of the articles of association with the following wording:/n Article 3a Capital Band/n The Company has a capital band between/n CHF 1'353'289.90 (lower limit) and/n CHF 2'029'934.84 (upper limit). The Board of Direc-/n tors is authorized to increase the share capital up to/n the upper limit at any time and as often as required/n until 25 June 2028./n Artikel 3a Kapitalband/n Die Gesellschaft hat ein Kapitalband zwischen/n CHF 1'353'289.90 (untere Grenze) und/n CHF 2'029'934.84 (obere Grenze). Der Verwal-/n tungsrat ist ermächtigt, bis zum 25. Juni 2028 das/n Aktienkapital jederzeit und beliebig oft bis zur obe-/n ren Grenze zu erhöhen./n The increase must be effected by issuing a maxi-/n mum of 33'832'247 registered shares with a par/n value of CHF 0.02, to be fully paid up. After a/n change in par value, the new par value shall also/n apply within the scope of the capital band. A capital/n reduction is excluded./n Die Erhöhung hat durch Ausgabe von maximal/n 33'832'247 vollständig zu liberierenden Namenak-/n tien im Nennwert von CHF 0.02 zu erfolgen. Nach/n einer Nennwertveränderung gilt der neue Nennwert/n auch im Rahmen des Kapitalbandes. Eine/n Kapitalherabsetzung wird ausgeschlossen./n This resolution is conditional on the Board of Directors having implemented the capital increase for the/n 18'879'032 registered shares issued from the conditional capital but not yet reflected in the commercial/n register as of the date of the invitation./n Background: At the Company's annual general meeting in 2023, the shareholders approved the crea-/n tion of a capital band in the amount of 50% of the Company's then current ordinary share capital. The/n Board proposes to increase this again to maintain the roughly 50% ratio originally envisaged. With this/n request, the Company intends to gain the flexibility to conduct a meaningful financing without separate/n shareholder approval, as speed will likely be a key factor if the Company is to secure a financing and/n emerge from moratorium./n4. Increase of the Conditional Share Capital for Bonds and Similar Debt Instruments/n The Board of Directors proposes to increase the conditional share capital for bonds and similar debt/n instruments by 28'318'548 registered shares with a nominal value of CHF 0.02 each and to amend/n article 3b paragraph 1 of the articles of association to read as follows:/n Art. 3b Conditional Capital for Bonds and/n Similar Debt Instruments/n The share capital of the Company shall be increased/n by a maximum amount of CHF 591'780.38 through/n the issuance of a maximum of 29'589'019 registered/n shares, payable in full, each with a nominal value of/n CHF 0.02 through the exercise of conversion and/or/n option rights granted in connection with bonds or/n similar instruments, issued or to be issued by the/n Company or by subsidiaries of the Company, includ-/n ing convertible debt instruments. The exercise of the/n conversion and/or option rights and the waiver of/n such right shall be made in writing on paper or in/n electronic form./n Art. 3b Bedingtes Kapital für Anlei-/n hensobligationen oder ähnliche/n Instrumente/n Das Aktienkapital der Gesellschaft wird im Maximal-/n betrag von CHF 591'780.38 durch Ausgabe von/n höchstens 29'589'019 vollständig zu liberierenden/n Namenaktien mit einem Nennwert von CHF 0.02 je/n Aktie erhöht durch die Ausübung von Wandlungs-/n und/oder Optionsrechten, welche im Zusammen-/n hang mit von der Gesellschaft oder ihren Tochterge-/n sellschaften emittierten oder noch zu emittierenden/n Anleihensobligationen oder ähnlichen Instrumenten/n eingeräumt wurden oder werden, einschliesslich/n Wandelanleihen. Die Form der Ausübung der/n Wandlungs- und/oder Optionsrechte und des Ver-/n zichts auf dieses Recht erfolgt auf schriftlichem Weg/n auf Papier oder in elektronischer Form./n This resolution is conditional on the Board of Directors having implemented the capital increase for the/n 18'879'032 registered shares issued from the conditional capital but not yet reflected in the commercial/n register as of the date of the invitation./n Background: The Board proposes to adjust the conditional capital for bonds and similar debt instru-/n ments as set out above in order to facilitate potential financing activities of the Company. Conditional/n capital has certain advantages over the capital band and is aimed at ensuring flexibility in the capital/n structure of the Company, typically for smaller and short-term financing needs, which will likely be/n essential if the Company is to emerge from moratorium./n5. Election to the Board of Directors/n The Board of Directors proposes to re-elect Jeffrey D. Wager as chairman and member of the Board,/n to re-elect Dennis Ausiello, Bernard Bollag, Robert Clarke, Dan Hartmann and Kuno Sommer as mem-/n bers of the Board, each for the term until the next Annual Shareholders' Meeting. The Board of Direc-/n tors further proposes to elect Carl-Åke Carlsson as a new member of the Board with a term until the/n next Annual Shareholders' Meeting./n Short Bio Carl-Åke Carlsson/n Mr.

Carl-Åke Carlsson brings over three decades of leadership and strategic experience in the phar-/n maceutical industry and embodies Scandinavian diversity:
Born in Norway with Swedish ancestry and/n having spent over a decade living and working in Denmark. Carl-Åke was CEO of Xellia Pharmaceu-/n ticals for 15 years, specializing in anti-infective and critical care treatments. Under his leadership, Xellia/n transitioned from a Scandinavian entity to a global contender, boasting annual sales to USD 300 million/n and a robust team of around 1,800 employees./n 5.a Re-Election of Jeffrey D. Wager as chairman and member of the Board/n 5.b Re-Election of Dennis Ausiello as member of the Board/n 5.c Re-Election of Bernard Bollag as member of the Board/n 5.d Re-Election of Robert Clarke as member of the Board/n 5.e Re-Election of Dan Hartmann as member of the Board/n 5.f Re-Election of Kuno Sommer as member of the Board/n 5.g Election of Carl-Åke Carlsson as member of the Board./n6. Election of the auditors/n The Board of Directors proposes to re-elect the Deloitte AG as auditors, for the term until the next/n Annual Shareholders' Meeting./n7. Election of the Independent Proxy/n The Board of Directors proposes to re-elect lic. iur. Marius Meier, Attorney at Law and Public Notary,/n Lautengartenstrasse 7, CH-4052 Basel, Switzerland, as independent proxy for the term until the next/n Annual Shareholders' Meeting./n8. Election of the Members of the Compensation Committee/n The Board of Dir